• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

杜氏利什曼原虫表面糖缀合物GP36是岩藻糖-甘露糖配体(FML)的主要免疫原成分。

Leishmania donovani surface glycoconjugate GP36 is the major immunogen component of the fucose-mannose ligand (FML).

作者信息

Palatnik-de-Sousa C B, Dutra H S, Borojevic R

机构信息

Departamento de Microbiologia Geral, Universidade Federal do Rio de Janeiro, Brazil.

出版信息

Acta Trop. 1993 Mar;53(1):59-72. doi: 10.1016/0001-706x(93)90006-w.

DOI:10.1016/0001-706x(93)90006-w
PMID:8096110
Abstract

Leishmania donovani promastigote glycoconjugate ligands, studied in our laboratory, that interact with the internalization receptors on BALB/c macrophages: the 'fucose mannose ligand' (FML), the 'phosphate mannogalactan ligand' (PMGL), and the 'lipopeptidephosphoglycan' (LPPD), interfered also with interaction between amastigotes and host cells in vitro. Among the three compounds studied, the FML was shown to be the most potent inhibitor of both promastigote and amastigote internalization, and to be present on parasite surface during the vertebrate-host cycle. The FML, but not the other two glycoconjugates, is a potent immunogen in rabbits (ELISA, agglutination and immuno-blots). Rabbit hyperimmune sera recognized essentially the 36 kDa band of FML. Mouse monoclonal antibodies against FML recognized either the 36 kDa or the 55 kDa band. No cross-reactivity between these two FML components was detected. No antigenic similarity could be detected between the 36 and 55 kDa bands of FML and the 'GP63' (promastigote surface proteinase) major surface leishmanial antigen. The 36 kDa-glycoprotein was identified as the major FML antigenic fraction and designated 'GP36'. The integrity of the glycidic moiety was necessary for its antigenicity. This L. donovani surface glycoprotein is apparently one of the major molecules involved in interactions between the parasite and the vertebrate host.

摘要

在我们实验室研究的杜氏利什曼原虫前鞭毛体糖缀合物配体,可与BALB/c巨噬细胞上的内化受体相互作用:“岩藻糖甘露糖配体”(FML)、“磷酸甘露半乳聚糖配体”(PMGL)和“脂肽磷酸聚糖”(LPPD),在体外也会干扰无鞭毛体与宿主细胞之间的相互作用。在所研究的这三种化合物中,FML被证明是前鞭毛体和无鞭毛体内化的最有效抑制剂,并且在脊椎动物-宿主周期中存在于寄生虫表面。FML,而非其他两种糖缀合物,是兔体内的一种有效免疫原(ELISA、凝集和免疫印迹)。兔超免疫血清主要识别FML的36 kDa条带。抗FML的小鼠单克隆抗体识别36 kDa或55 kDa条带。未检测到这两种FML成分之间的交叉反应性。在FML的36 kDa和55 kDa条带与“GP63”(前鞭毛体表面蛋白酶)利什曼原虫主要表面抗原之间未检测到抗原相似性。36 kDa糖蛋白被鉴定为主要的FML抗原部分,并命名为“GP36”。糖部分的完整性对其抗原性是必需的。这种杜氏利什曼原虫表面糖蛋白显然是参与寄生虫与脊椎动物宿主之间相互作用的主要分子之一。

相似文献

1
Leishmania donovani surface glycoconjugate GP36 is the major immunogen component of the fucose-mannose ligand (FML).杜氏利什曼原虫表面糖缀合物GP36是岩藻糖-甘露糖配体(FML)的主要免疫原成分。
Acta Trop. 1993 Mar;53(1):59-72. doi: 10.1016/0001-706x(93)90006-w.
2
Inhibition of Leishmania donovani promastigote internalization into murine macrophages by chemically defined parasite glycoconjugate ligands.通过化学确定的寄生虫糖缀合物配体抑制杜氏利什曼原虫前鞭毛体内化到小鼠巨噬细胞中。
Infect Immun. 1989 Mar;57(3):754-63. doi: 10.1128/iai.57.3.754-763.1989.
3
The FML (Fucose Mannose Ligand) of Leishmania donovani. a new tool in diagnosis, prognosis, transfusional control and vaccination against human kala-azar.
Rev Soc Bras Med Trop. 1996 Mar-Apr;29(2):153-63. doi: 10.1590/s0037-86821996000200008.
4
Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani.
Vaccine. 2001 Apr 30;19(23-24):3104-15. doi: 10.1016/s0264-410x(01)00031-7.
5
Experimental murine Leishmania donovani infection: immunoprotection by the fucose-mannose ligand (FML).
Braz J Med Biol Res. 1994 Feb;27(2):547-51.
6
Haemolytic activities of plant saponins and adjuvants. Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani.植物皂苷和佐剂的溶血活性。地中海佩里安德拉皂苷对杜氏利什曼原虫FML抗原体液反应的影响。
Vaccine. 1997 Jun;15(9):1024-9. doi: 10.1016/s0264-410x(96)00292-7.
7
Leishmania donovani: titration of antibodies to the fucose-mannose ligand as an aid in diagnosis and prognosis of visceral leishmaniasis.
Trans R Soc Trop Med Hyg. 1995 Jul-Aug;89(4):390-3. doi: 10.1016/0035-9203(95)90022-5.
8
A new approach to the phylogeny of Leishmania: species specificity of glycoconjugate ligands for promastigote internalization into murine macrophages.利什曼原虫系统发育的新方法:前鞭毛体内化进入小鼠巨噬细胞的糖缀合物配体的物种特异性
Parasitol Res. 1990;76(4):289-93. doi: 10.1007/BF00928181.
9
The major Leishmania donovani chagasi surface glycoprotein in tunicamycin-resistant promastigotes.抗衣霉素前鞭毛体中主要的杜氏利什曼原虫恰加斯亚种表面糖蛋白
J Immunol. 1990 Jun 15;144(12):4825-34.
10
Evidence that Leishmania donovani utilizes a mannose receptor on human mononuclear phagocytes to establish intracellular parasitism.杜氏利什曼原虫利用人类单核吞噬细胞上的甘露糖受体来建立细胞内寄生关系的证据。
J Immunol. 1986 Jun 15;136(12):4681-8.

引用本文的文献

1
Cytokine profile and nitric oxide levels in peritoneal macrophages of BALB/c mice exposed to the fucose-mannose ligand of Leishmania infantum combined with glycyrrhizin.BALB/c 小鼠腹腔巨噬细胞细胞因子谱和一氧化氮水平与结合甘草酸的婴儿利什曼原虫岩藻糖甘露糖配体暴露
Parasit Vectors. 2020 Jul 20;13(1):363. doi: 10.1186/s13071-020-04243-7.
2
The Delay in the Licensing of Protozoal Vaccines: A Comparative History.原生动物疫苗的许可延迟:比较历史。
Front Immunol. 2020 Mar 6;11:204. doi: 10.3389/fimmu.2020.00204. eCollection 2020.
3
Nucleoside Hydrolase NH 36: A Vital Enzyme for the Genus in the Development of T-Cell Epitope Cross-Protective Vaccines.
核苷水解酶 NH36:T 细胞表位交叉保护疫苗研发中属水平至关重要的酶。
Front Immunol. 2019 Apr 16;10:813. doi: 10.3389/fimmu.2019.00813. eCollection 2019.
4
NH36 and F3 Antigen-Primed Dendritic Cells Show Preserved Migrating Capabilities and CCR7 Expression and F3 Is Effective in Immunotherapy of Visceral Leishmaniasis.NH36 和 F3 抗原致敏树突状细胞保持迁移能力和 CCR7 表达,F3 可有效用于内脏利什曼病的免疫治疗。
Front Immunol. 2018 May 7;9:967. doi: 10.3389/fimmu.2018.00967. eCollection 2018.
5
Expression and purification of an engineered, yeast-expressed Leishmania donovani nucleoside hydrolase with immunogenic properties.具有免疫原性的工程化酵母表达杜氏利什曼原虫核苷水解酶的表达与纯化
Hum Vaccin Immunother. 2016 Jul 2;12(7):1707-20. doi: 10.1080/21645515.2016.1139254. Epub 2016 Feb 2.
6
Cross-Protective Immunity to Leishmania amazonensis is Mediated by CD4+ and CD8+ Epitopes of Leishmania donovani Nucleoside Hydrolase Terminal Domains.美洲利什曼原虫核苷水解酶末端结构域的 CD4+ 和 CD8+ 表位介导对利什曼原虫的交叉保护免疫。
Front Immunol. 2014 May 1;5:189. doi: 10.3389/fimmu.2014.00189. eCollection 2014.
7
Identifying vaccine targets for anti-leishmanial vaccine development.鉴定抗利什曼原虫疫苗开发的疫苗靶点。
Expert Rev Vaccines. 2014 Apr;13(4):489-505. doi: 10.1586/14760584.2014.894467.
8
Development of Leishmania vaccines: predicting the future from past and present experience.利什曼原虫疫苗的研发:从过去和现在的经验预测未来
J Biomed Res. 2013 Mar;27(2):85-102. doi: 10.7555/JBR.27.20120064. Epub 2012 Sep 30.
9
The efficacy of L. (L.) chagasi excreted-secreted antigens (ESAs) for visceral leishmaniasis diagnosis is due to low levels of cross-reactivity.L. (L.) chagasi 排泄物分泌抗原(ESAs)在利什曼原虫病诊断中的有效性归因于其较低的交叉反应性。
Am J Trop Med Hyg. 2013 Mar;88(3):559-65. doi: 10.4269/ajtmh.12-0587. Epub 2013 Jan 16.
10
Development of Vaccines against Visceral Leishmaniasis.内脏利什曼病疫苗的研制。
J Trop Med. 2012;2012:892817. doi: 10.1155/2012/892817. Epub 2011 Sep 5.